Clinical trial
A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
NCT06281678 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 8, 2024
- Completion date
- December 31, 2026
- Enrollment
- 178 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer, melanoma, non-small cell lung cancer, renal cell cancer